Information Provided By: 
Fly News Breaks for October 5, 2015
MDCO
Oct 5, 2015 | 07:31 EDT
After examining surveys and speaking with experts, RBC Capital says that the uptake of The Medicines Co's ALN-PCSsc treatment has been strong among anti-PCSK9 patients, reaching 20%-30%. The firm estimates that the company could conservatively generate $9B-$18B in revenue from the drug. It believes that the product is "a potential game changer and valuation driver" for the company. RBC keeps a $46 price target and Outperform rating on the shares.
News For MDCO From the Last 2 Days
There are no results for your query MDCO
